Guest guest Posted December 28, 2008 Report Share Posted December 28, 2008 This laboratory study was a joint effort by Dr. Israel Barken of the Prostate Cancer Research and Educational Foundation, Moshe Rogosnitzky of MedInsight Research Institute, and Dr. Jack Geller of UC San Diego. Noscapine has previously been studied as a treatment for breast, ovarian, colon, lung and brain cancer and for various lymphomas, chronic lymphocytic leukemia and melanoma. This study, however, is the first to demonstrate its effectiveness in treating prostate cancer. Noscapine is a naturally-occurring substance, a non-addictive derivative of opium. As a natural substance, noscapine cannot be patented, which has limited the potential for clinical trials. Rogosnitzky notes that drug companies are generally unwilling to underwrite expensive clinical trials without being able to recoup their investment. A synthetic derivative of noscapine has been patented but has not yet reached the clinical testing phase. Click on the below link for the full story:<http://www.medicalnewstoday.com/articles/133891.php> Quote Link to comment Share on other sites More sharing options...
Recommended Posts
Join the conversation
You are posting as a guest. If you have an account, sign in now to post with your account.
Note: Your post will require moderator approval before it will be visible.